Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Merck & Co., Inc. (MRK) vs BIO-TECHNE Corp (TECH) Price & Performance

Merck & Co., Inc.Trade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs BIO-TECHNE Corp — how do they compare? Merck & Co., Inc. trades at $130.2 (market cap $321.77B), while BIO-TECHNE Corp trades at $72 (market cap $11.24B). The key difference: Merck & Co., Inc. is far larger — about 28.6× BIO-TECHNE Corp's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.

MRKTECH
Market Cap
$321.77B$11.24B
Sector
HealthHealth
52-Week High
$131.84$72.29
52-Week Low
$77.60$43.31
Enterprise Value
$368.53B$11.32B
Dividend Yield
2.61%0.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.

The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.

BIO-TECHNE Corp

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH